series-b
Stage
2014
Founded
3
Investors
About
Pep-Therapy is a clinical-stage biotechnology company developing a new generation of targeted therapeutic peptides for oncology. Its lead product, Pepsolyn®, is in Phase 1/2a clinical trials for advanced solid tumors.
Explore Pep-Therapy's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.